Physician profile
Katherine Kulas
NPI 1174218226
$4,829.86
in general payments reported to CMS, 2019-2025
23 companies · $2,029 in 2025
The $2,029 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,411 · 2024: $1,390 · 2025: $2,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,436 · Education: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,435.93 |
| Education | $393.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,326.22 | 2023-2025 | Stelara, Tremfya |
| Abbvie INC. | $1,250.04 | 2023-2025 | |
| Madrigal Pharmaceuticals | $456.61 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $280.47 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $266.81 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $236.67 | 2025 | Epclusa, Livdelzi |
| Genzyme Corporation | $204.91 | 2023-2025 | |
| Ardelyx, INC. | $171.62 | 2023 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $125.00 | 2023 | |
| Intercept Pharmaceuticals, INC. | $123.81 | 2024 | |
| Janssen Scientific Affairs, LLC | $68.49 | 2023 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.48 | 2023 | Trulance, Plenvu, Xifaxan |
| Octapharma USA, INC. | $40.33 | 2024-2025 | Fibryga |
| Celgene Corporation | $34.58 | 2023 | Zeposia |
| Pfizer INC. | $29.30 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $25.09 | 2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $21.42 | 2025 | Rebyota |
| Elucent Medical | $20.67 | 2025 | |
| Novo Nordisk INC | $20.06 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $19.57 | 2024 | Keytruda, Lynparza |
| Csl Behring | $19.53 | 2023 | Kcentra |
| Phathom Pharmaceuticals, INC. | $17.95 | 2025 | Voquezna |
| Becton, Dickinson and Company | $16.23 | 2023 | Rotarexs 6 F X 135 Cm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Kulas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.